US Stock MarketDetailed Quotes

AIM AIM ImmunoTech

Watchlist

0.1965
-0.0339-14.71%

Trading Nov 19 12:24 ET

12.52MMarket Cap-418P/E (TTM)

AIM ImmunoTech Stock Forum

Trytosaveabit

4 hours ago

Update

$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
4 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data were published on Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating AIM ImmunoTech's drug Ampligen® (also known as rintatolimod) ...

Jaguar8

Nov 14 14:32

13G

$AIM ImmunoTech (AIM.US)$
AIM ImmunoTech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(6.84%),Steven Boyd(6.84%)

Stock_Drift

Oct 3 15:39

After Hours Ticks. 10/3…4:47pm EST.

$Intellinetics (INLX.US)$ $Lm Funding America (LMFA.US)$ $Beyond Air (XAIR.US)$ $Jianzhi Education (JZ.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Martin Midstream (MMLP.US)$ $Edesa Biotech (EDSA.US)$ $AIM ImmunoTech (AIM.US)$ $Smart Sand (SND.US)$ $SPI Energy (SPI.US)$ $Renovaro (RENB.US)$ $Phoenix Motor (PEV.US)$

Trytosaveabit

Oct 3 15:13

Hehehe

$Venus Concept (VERO.US)$ This get news that they are filing for a patent and jumps 40%! $AIM ImmunoTech (AIM.US)$ is granted a patent and price falls! Hehehe

Trytosaveabit

Oct 3 07:50

News

$AIM ImmunoTech (AIM.US)$ Reuters
4 mins ago
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

Stock_Drift

Sep 25 04:10

9/25 Pre_Market 🚨🚨

$AtlasClear (ATCH.US)$ $VS MEDIA Holdings (VSME.US)$ $Motorsport Games (MSGM.US)$ $Eliem Therapeutics (ELYM.US)$ $ParaZero Technologies (PRZO.US)$ $AIM ImmunoTech (AIM.US)$ $XChange TEC (XHG.US)$
📊⚡️📊

MARKET-TEST-DUMMY

Sep 23 05:11

What's up here

$AIM ImmunoTech (AIM.US)$

Jaguar8

Sep 19 07:23

NEWS

$AIM ImmunoTech (AIM.US)$
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally wel...

Trytosaveabit

Aug 20 07:32

Update

$AIM ImmunoTech (AIM.US)$ Reuters
2 mins ago
AIM ImmunoTech Announces Print Publication and Further Positive Findings From a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research